NCT06454630: A reported trial by Regeneron Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT06454630 |
|---|---|
| Title | A Phase 2, Multicenter, Randomized, Open-Label, Active Control Study of REGN7508, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 27, 2024 |
| Completion date | Nov. 19, 2024 |
| Required reporting date | Nov. 19, 2027, midnight |
| Actual reporting date | Jan. 20, 2026 |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |